GlassScriptPhysician profile
Alexander Frank
NPI 1164450573
$3,090,489.01
in general payments reported to CMS, 2019-2025
24 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,376 · 2020: $630 · 2021: $539 · 2022: $915 · 2023: $570 · 2024: $3.1M · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $3.1M · Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $3,082,225.00 |
| Food and Beverage | $803.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Skye Orthobiologics LLC | $3,082,225.00 | 2024 | |
| Janssen Pharmaceuticals, INC | $4,468.61 | 2019 | |
| Acadia Pharmaceuticals INC | $1,157.03 | 2019-2025 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $684.27 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $552.34 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $257.90 | 2019-2020 | |
| Corium, LLC | $187.47 | 2022-2023 | Adlarity, Azstarys |
| Gilead Sciences, INC. | $163.99 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $136.24 | 2025 | |
| Sun Pharmaceutical Industries INC. | $128.64 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $91.95 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $77.25 | 2019-2020 | |
| Ucb, INC. | $61.91 | 2020-2023 | Nayzilam |
| Smith+Nephew, INC. | $52.14 | 2021 | |
| Glaxosmithkline, LLC. | $36.16 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $35.33 | 2022-2023 | Perseris |
| Lilly USA, LLC | $32.26 | 2022-2023 | Trulicity |
| Sumitomo Pharma America, INC. | $26.79 | 2023 | Aptiom |
| Urovant Sciences INC | $23.01 | 2022 | |
| Amarin Pharma, INC. | $20.86 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.73 | 2021 | |
| Kyowa Kirin, INC. | $17.73 | 2021 | |
| Dexcom, INC. | $17.12 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.28 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.